paul

Base Cuatro's liquid biopsy analyzes RNA expression patterns from a standard blood draw to project tissue-specific anomalies across 30+ organs, detecting subclinical dysfunction years before phenotypic manifestation — a shift from reactive diagnostics to preventive molecular surveillance.

Because women were excluded from clinical trials until 1992, existing biological models are trained on male data, causing women to be diagnosed 6+ years later than men across 600+ diseases; Base Cuatro's female-specific model trained exclusively on women's data creates a physiological atlas to close this gap, starting with fertility and menopause-related multi-organ risk.

By quantifying RNA expression (which genes are active) rather than static DNA methylation, Base Cuatro's clocks identify which metabolic pathways drive accelerated aging in each tissue, enabling targeted lifestyle or therapeutic interventions — solving the 'non-actionable' problem of first-generation epigenetic clocks.